Charles A. Rowland Jr., Director at Nabriva Therapeutics plc (NBRV), sold 777 shares at $1.20 ($932) on 2021-08-02, disclosed to the SEC on 2021-08-04.
Open-market sale of $932 NBRV by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| VKTX | SELL | 2023-05-18 | $1.0M | — | Filing → |
| GBIO | BUY | 2022-09-20 | $83K | — | Filing → |
| GBIO | BUY | 2022-09-19 | $552K | — | Filing → |